 Andrew Kent
Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 8 | 2026 | 688 | 2.310 |
Why?
| | Hematologic Neoplasms | 2 | 2023 | 168 | 1.310 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2024 | 699 | 1.040 |
Why?
| | Hematopoietic Stem Cells | 2 | 2026 | 435 | 0.860 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 23 | 0.840 |
Why?
| | Inflammasomes | 1 | 2025 | 144 | 0.780 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2025 | 169 | 0.780 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2024 | 103 | 0.780 |
Why?
| | Transplantation Conditioning | 1 | 2024 | 191 | 0.760 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2025 | 337 | 0.740 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 76 | 0.720 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2021 | 16 | 0.690 |
Why?
| | Dog Diseases | 1 | 2021 | 106 | 0.630 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 297 | 0.590 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1997 | 0.580 |
Why?
| | Urinary Tract Infections | 1 | 2021 | 210 | 0.580 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2021 | 673 | 0.510 |
Why?
| | Genetic Variation | 1 | 2021 | 976 | 0.470 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 4 | 2026 | 280 | 0.440 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1150 | 0.390 |
Why?
| | Sulfonamides | 4 | 2026 | 583 | 0.390 |
Why?
| | Signal Transduction | 3 | 2025 | 5223 | 0.350 |
Why?
| | Stem Cell Transplantation | 2 | 2023 | 189 | 0.320 |
Why?
| | Anti-Bacterial Agents | 1 | 2021 | 1925 | 0.320 |
Why?
| | Neoplasms | 3 | 2021 | 2913 | 0.310 |
Why?
| | Immunotherapy, Adoptive | 2 | 2022 | 342 | 0.270 |
Why?
| | Azacitidine | 2 | 2026 | 157 | 0.230 |
Why?
| | T-Lymphocyte Subsets | 2 | 2021 | 420 | 0.230 |
Why?
| | Niacinamide | 1 | 2026 | 104 | 0.230 |
Why?
| | Stromal Cells | 1 | 2025 | 121 | 0.210 |
Why?
| | Myelodysplastic Syndromes | 1 | 2026 | 165 | 0.210 |
Why?
| | ras Proteins | 1 | 2025 | 150 | 0.200 |
Why?
| | Lymphoma, B-Cell | 1 | 2025 | 141 | 0.190 |
Why?
| | Gamma Rays | 1 | 2023 | 57 | 0.190 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2023 | 78 | 0.190 |
Why?
| | Carcinogenesis | 1 | 2025 | 228 | 0.190 |
Why?
| | Phagocytes | 1 | 2023 | 80 | 0.180 |
Why?
| | Graft vs Host Disease | 1 | 2024 | 279 | 0.170 |
Why?
| | Cell Engineering | 1 | 2021 | 15 | 0.170 |
Why?
| | Humans | 15 | 2026 | 145750 | 0.170 |
Why?
| | CD3 Complex | 1 | 2021 | 112 | 0.160 |
Why?
| | Genetic Engineering | 1 | 2021 | 88 | 0.160 |
Why?
| | Lipids | 1 | 2025 | 707 | 0.160 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 145 | 0.160 |
Why?
| | United Kingdom | 1 | 2021 | 358 | 0.160 |
Why?
| | Genetic Counseling | 1 | 2020 | 80 | 0.150 |
Why?
| | Dogs | 1 | 2021 | 478 | 0.150 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 563 | 0.150 |
Why?
| | Multiprotein Complexes | 1 | 2021 | 172 | 0.150 |
Why?
| | Recurrence | 1 | 2023 | 1139 | 0.150 |
Why?
| | Phenylurea Compounds | 1 | 2020 | 119 | 0.150 |
Why?
| | Single-Cell Analysis | 1 | 2023 | 362 | 0.150 |
Why?
| | Disease Susceptibility | 1 | 2021 | 344 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2026 | 1969 | 0.150 |
Why?
| | Benzimidazoles | 1 | 2020 | 189 | 0.140 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 735 | 0.140 |
Why?
| | Biomarkers, Tumor | 1 | 2025 | 1329 | 0.140 |
Why?
| | Minority Groups | 1 | 2020 | 285 | 0.140 |
Why?
| | Animals | 6 | 2025 | 38100 | 0.140 |
Why?
| | Mice, Knockout | 1 | 2025 | 3130 | 0.130 |
Why?
| | Cell Proliferation | 1 | 2025 | 2514 | 0.130 |
Why?
| | Adaptive Immunity | 2 | 2015 | 167 | 0.130 |
Why?
| | Carrier Proteins | 1 | 2021 | 729 | 0.120 |
Why?
| | Disease Management | 1 | 2021 | 653 | 0.120 |
Why?
| | Retrospective Studies | 3 | 2024 | 17322 | 0.120 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5992 | 0.120 |
Why?
| | Immunotherapy | 1 | 2021 | 667 | 0.120 |
Why?
| | Protein Binding | 1 | 2021 | 2240 | 0.110 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2015 | 177 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2026 | 2219 | 0.100 |
Why?
| | Intestine, Small | 1 | 2015 | 167 | 0.100 |
Why?
| | Receptors, Notch | 1 | 2014 | 90 | 0.100 |
Why?
| | Cell Communication | 1 | 2015 | 328 | 0.100 |
Why?
| | Treatment Outcome | 2 | 2026 | 11793 | 0.090 |
Why?
| | Mice | 4 | 2025 | 18357 | 0.090 |
Why?
| | Neuronal Apoptosis-Inhibitory Protein | 1 | 2012 | 3 | 0.090 |
Why?
| | Stress, Physiological | 1 | 2015 | 443 | 0.090 |
Why?
| | Celiac Disease | 1 | 2015 | 311 | 0.090 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2012 | 187 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2014 | 923 | 0.080 |
Why?
| | Toll-Like Receptors | 1 | 2012 | 193 | 0.080 |
Why?
| | Calcium-Binding Proteins | 1 | 2012 | 221 | 0.080 |
Why?
| | Cancer Vaccines | 1 | 2012 | 162 | 0.080 |
Why?
| | Female | 6 | 2026 | 79025 | 0.080 |
Why?
| | Mutation | 1 | 2021 | 4090 | 0.080 |
Why?
| | Biomarkers | 1 | 2021 | 4302 | 0.070 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 675 | 0.070 |
Why?
| | Prospective Studies | 1 | 2021 | 8075 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2015 | 1134 | 0.070 |
Why?
| | Middle Aged | 3 | 2026 | 36297 | 0.070 |
Why?
| | Young Adult | 1 | 2024 | 14250 | 0.060 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2026 | 26 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2014 | 2051 | 0.060 |
Why?
| | Remission Induction | 1 | 2026 | 307 | 0.050 |
Why?
| | Adolescent | 1 | 2024 | 22569 | 0.050 |
Why?
| | Adult | 2 | 2025 | 40867 | 0.050 |
Why?
| | Child | 1 | 2024 | 22738 | 0.050 |
Why?
| | Male | 4 | 2026 | 72992 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2023 | 143 | 0.050 |
Why?
| | Arabs | 1 | 2020 | 10 | 0.040 |
Why?
| | Israel | 1 | 2020 | 46 | 0.040 |
Why?
| | Survival Rate | 1 | 2025 | 2094 | 0.040 |
Why?
| | Aged | 3 | 2026 | 26212 | 0.040 |
Why?
| | Machine Learning | 1 | 2025 | 587 | 0.040 |
Why?
| | North America | 1 | 2020 | 303 | 0.040 |
Why?
| | Lymphocyte Activation | 2 | 2014 | 1133 | 0.040 |
Why?
| | Cytokines | 1 | 2026 | 2069 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 483 | 0.030 |
Why?
| | Counseling | 1 | 2020 | 401 | 0.030 |
Why?
| | Prognosis | 1 | 2025 | 4329 | 0.030 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2015 | 13 | 0.030 |
Why?
| | Italy | 1 | 2015 | 117 | 0.030 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2015 | 75 | 0.030 |
Why?
| | Interleukin-15 | 1 | 2015 | 95 | 0.030 |
Why?
| | GTP-Binding Proteins | 1 | 2015 | 153 | 0.030 |
Why?
| | Heat-Shock Proteins | 1 | 2015 | 139 | 0.030 |
Why?
| | Transglutaminases | 1 | 2015 | 159 | 0.030 |
Why?
| | Transduction, Genetic | 1 | 2014 | 132 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2014 | 200 | 0.030 |
Why?
| | Orthomyxoviridae Infections | 1 | 2014 | 71 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 337 | 0.030 |
Why?
| | Influenza A virus | 1 | 2014 | 119 | 0.020 |
Why?
| | Cell Separation | 1 | 2014 | 306 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2015 | 199 | 0.020 |
Why?
| | Qualitative Research | 1 | 2020 | 1676 | 0.020 |
Why?
| | Flagellin | 1 | 2012 | 19 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1165 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2014 | 2191 | 0.020 |
Why?
| | Transcriptome | 1 | 2014 | 1043 | 0.020 |
Why?
| | Autoantibodies | 1 | 2015 | 1509 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3634 | 0.020 |
Why?
| | Phenotype | 1 | 2015 | 3170 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 1146 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3551 | 0.010 |
Why?
| | Risk Factors | 1 | 2015 | 10916 | 0.010 |
Why?
| | United States | 1 | 2015 | 16122 | 0.010 |
Why?
|
|
Kent's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|